Skip NavigationSkip to Content

Determining KRAS4B-Targeting Compound Specificity by Top-Down Mass Spectrometry

  1. Author:
    D'Ippolito,Robert
    Scheidemantle,Grace
    Rabara,Dana
    Abreu Blanco, Maria
    Ramakrishnan,Nitya
    Widmeyer, Stephanie R T
    Messing,Simon
    Turner,David
    Maciag,Anna
    Stephen,Andy
    Esposito,Dom
    McCormick, Frank
    Nissley,Dwight
    Dehart,Caroline
  2. Author Address

    NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA., NCI RAS Initiative, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. caroline.dehart@nih.gov.,
    1. Year: 2024
  1. Journal: Methods in Molecular Biology (Clifton, N.J.)
    1. 2823
    2. Pages: 291-310
  2. Type of Article: Article
  1. Abstract:

    We present a novel method to determine engagement and specificity of KRAS4B-targeting compounds in vitro. By employing top-down mass spectrometry (MS), which analyzes intact and modified protein molecules (proteoforms), we can directly visualize and confidently characterize each KRAS4B species within compound-treated samples. Moreover, by employing targeted MS2 fragmentation, we can precisely localize each compound molecule to a specific residue on a given KRAS4B proteoform. This method allows us to comprehensively evaluate compound specificity, clearly detect nonspecific binding events, and determine the order and frequency with which they occur. We provide two proof-of-concept examples of our method employing publicly available compounds, along with detailed protocols for sample preparation, top-down MS data acquisition, targeted proteoform MS2 fragmentation, and analysis of the resulting data. Our results demonstrate the concentration dependence of KRAS4B-compound engagement and highlight the ability of top-down MS to directly map compound binding location(s) without disrupting the KRAS4B primary structure. Our hope is that this novel method may help accelerate the identification of new successful targeted inhibitors for KRAS4B and other RAS isoforms. © 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

    See More

External Sources

  1. DOI: 10.1007/978-1-0716-3922-1_18
  2. PMID: 39052227

Library Notes

  1. Fiscal Year: FY2023-2024
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel